title: [Chronic hepatitis--new therapeutic options].
authors.affiliation: Med. Klinik C, Klinikum der Stadt Ludwigshafen gGmbH, Bremserstrasse 79, 67063 Ludwigshafen. MedCLu@t-online.de
authors.forename: J C
authors.initials: JC
authors.lastname: Arnold
authors.forename: W
authors.initials: W
authors.lastname: Stremmel
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D000075202:Contraindications; D004359:Drug Therapy, Combination; D016174:Hepacivirus / Q000302:isolation & purification; D006515:Hepatitis B virus / Q000302:isolation & purification; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage* / Q000009:adverse effects; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D019259:Lamivudine / Q000008:administration & dosage / Q000009:adverse effects; D011092:Polyethylene Glycols; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D012254:Ribavirin / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D000998:Antiviral Agents; D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a